Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
Status:
Completed
Trial end date:
2017-08-11
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and the best dose of MLN8237 (alisertib) when
given together with paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel)
in treating patients with solid malignancies that are metastatic or cannot be removed by
surgery. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. Drugs used in chemotherapy, such as nab-paclitaxel work by killing the cells
or by stopping them from dividing. Giving alisertib together with nab-paclitaxel may provide
a more effective anticancer treatment with fewer side effects.